Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system

References

• McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 83(5), 596–602 (2000).
   PubMed Web of Science ®Google Scholar
• American Heart Association. Heart Disease and Stroke Statistics–2004 update. Dallas: American Heart Association,TX, USA (2004).
   Google Scholar
• Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am. Heart J. 133(6), 703–712 (1997).
   PubMed Web of Science ®Google Scholar
• MacIntyre K, Capewell S, Stewart S et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation 102(10), 1126–1131 (2000).
   PubMed Web of Science ®Google Scholar
• Siniorakis E, Arvanitakis S, Voyatzopoulos G et al. Hemodynamic classification in acute myocardial infarction. Chest 117(5), 1286–1290 (2000).
   Google Scholar
• Davis RC, Hobbs FD, Lip GY. ABC of heart failure. History and epidemiology. Br. Med. J. 320 (7226), 39–42 (2000).
   Google Scholar
• Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc. Res. 42(2), 270–283 (1999).
   PubMed Web of Science ®Google Scholar
• Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium dependent vasodilation is attenuated in patients with heart failure. Circulation 84 (4), 1589–1596 (1991).
   Google Scholar
• Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81(4), 1161–1172 (1990).
   PubMed Web of Science ®Google Scholar
• Anand IS, Liu D, Chugh SS et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 96(11), 974–3984 (1997).
   Google Scholar
• Anversa P, Beghi C, Kikkawa Y, Olivetti G. Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth. Circ. Res. 58(1), 26–37 (1986).
   PubMed Web of Science ®Google Scholar
• Yue P, Long CS, Austin R, Chang KC, Simpson PC, Massie BM. Post-infarction heart failure in the rat is associated with distinct alterations in cardiac myocyte molecular phenotype. J. Mol. Cell. Cardiol. 30(8), 1615–1630 (1998).
   Google Scholar
• Roberts CS, Maclean D, Maroko P, Kloner RA. Early and late remodeling of the left ventricle after acute myocardial infarction. Am. J. Cardiol. 54(3), 407–410 (1984).
   Google Scholar
• Pfeffer JM. Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibition. Am. J. Cardiol. 68(14), 17D–25D (1991).
   Google Scholar
• Nelissen-Vrancken HJ, Debets JJ, Snoeckx LH, Daemen MJ, Smits JF. Time-related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. Circulation 93(2), 349–355 (1996).
   Google Scholar
• Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc. Res. 28(11), 1623–1628 (1994).
   PubMedGoogle Scholar
• Hanatani A, Yoshiyama M, Takeuchi K et al. Angiotensin II type 1–receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats. Jpn. J. Pharmacol. 78(1), 45–54 (1998).
   Google Scholar
• Gidh-Jain M, Huang B, Jain P, Glick G, El-Sherif N. Alterations in cardiac gene expression during ventricular remodeling following experimental myocardial infarction. J. Mol. Cell. Cardiol. 30 (3), 627–637 (1998).
   Google Scholar
• Iijima K, Geshi E, Nomizo A, Arata Y, Katagiri T. Alterations in sarcoplasmic reticulum and angiotensin II type 1 receptor gene expression after myocardial infarction in rats. Jpn. Circ. J. 62(6), 449–454 (1998).
   Google Scholar
• Sakai S, Miyauchi T, Yamaguchi I. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. Circulation 101(24), 2849–2853 (2000).
   PubMed Web of Science ®Google Scholar
• Lindpaintner K, Lu W, Neidermajer N et al. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J. Mol. Cell. Cardiol. 25(2), 133–143 (1993).
   PubMed Web of Science ®Google Scholar
• Abbate A, Biondi-Zoccai GG, Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J. Cell. Physiol. 193(2), 145–153 (2002).
   PubMed Web of Science ®Google Scholar
• Sigurdsson A, Held P, Swedberg KS. Short- and long-term neurohormonal activation following acute myocardial infarction. Am. Heart J. 126(5), 1068–1076 (1993).
   PubMed Web of Science ®Google Scholar
• Anthonio RL, van Veldhuisen DJ, van Gilst WH. Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both? J. Cardiovasc. Pharmacol. 32(Suppl. 1), S1–S8 (1998).
   Google Scholar
• Wollert KC, Drexler H. The renin– angiotensin system and experimental heart failure. Cardiovasc. Res. 43(4), 838–849 (1999).
   PubMed Web of Science ®Google Scholar
• Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation 87(Suppl. 5), IV90–IV96 (1993).
   Google Scholar
• Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 77(4), 721–730 (1988).
   PubMed Web of Science ®Google Scholar
• Tsuji H, Venditti FJ Jr, Evans JC, Larson MG, Levy D. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am. J. Cardiol. 74(3), 232–235 (1994).
   Google Scholar
• Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr. Hypertens. Rep. 2(5), 451–456 (2000).
   PubMedGoogle Scholar
• Tan LB, Schlosshan D, Barker D. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int. J. Cardiol. 96(3), 321–333 (2004).
   PubMedGoogle Scholar
• Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J. Mol. Cell. Cardiol. 30(3), 475–483 (1998).
   PubMed Web of Science ®Google Scholar
• Reid IA, Morris BJ, Ganong WF. The renin–angiotensin system. Annu. Rev. Physiol.40, 377–410 (1978).
   Google Scholar
• von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 89(1), 458–470 (1994).
   PubMed Web of Science ®Google Scholar
• van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 98(1), 73–81 (1998).
   PubMedGoogle Scholar
• Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J. Clin. Invest.100(2), 253–258 (1997).
   PubMed Web of Science ®Google Scholar
• Leenen FH, Skarda V, Yuan B, White R. Changes in cardiac Ang II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am. J. Physiol. Heart Circ. Physiol. 276(1 Pt 2), H317–H325 (1999).
   Google Scholar
• van Kats JP, Duncker DJ, Haitsma DB et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 102(13), 1556–1563 (2000).
   PubMed Web of Science ®Google Scholar
• Serneri GG, Boddi M, Cecioni I et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ. Res. 88(9), 961–968 (2001).
   Google Scholar
• Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ. Res. 87(5), E1–E9 (2000).
   PubMed Web of Science ®Google Scholar
• Pfeffer JM, Fischer TA, Pfeffer MA. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Ann. Rev. Physiol. 57, 805–826 (1995).
   Google Scholar
• Kohzuki M, Kanazawa M, Yoshida K et al. Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction. Jpn. Circ. J. 60(12), 972–980 (1996).
   Google Scholar
• Hokimoto S, Yasue H, Fujimoto K, Sakata R, Miyamoto E. Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction. Cardiovasc. Res. 29(5), 664–669 (1995).
   PubMedGoogle Scholar
• Schunkert H, Jackson B, Tang SS et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 87(4), 1328–1339 (1993).
   PubMed Web of Science ®Google Scholar
• Duncan AM, Burrell LM, Kladis A, Campbell DJ. Angiotensin and bradykinin peptides in rats with myocardial infarction. J. Card. Fail. 3(1), 41–52 (1997).
   Google Scholar
• Timmermans PB, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 15 (Suppl. D), 79–87 (1994).
   Google Scholar
• Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Invest. 95(1), 46–54 (1995).
   PubMed Web of Science ®Google Scholar
• Meggs LG, Coupet J, Huang H et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ. Res. 72(6), 1149–1162 (1993).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327 (10), 669–677 (1992).
   Google Scholar
• ISIS-4 collaborative group. Fourth International Study of Infarct Survival: protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. Am. J. Cardiol. 68(14), 87D–100D (1991).
   Google Scholar
• van Gilst WH, Kingma JH, Peels KH, Dambrink JH, St John SM. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of 1-year serial echocardiographic follow-up from the Captopril and Thrombolysis study (CATS). J. Am. Coll. Cardiol. 28(1), 114–121 (1996).
   Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327(10), 685–691 (1992).
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316(23), 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325(5), 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325(5), 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Borghi C, Marino P, Zardini P, Magnani B, Collatina S, Ambrosioni E. Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS). Am. J. Hypertens. 10(10 Pt 2), 247S–254S (1997).
   Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J. Am. Coll. Cardiol. 27(2), 337–344 (1996).
   PubMedGoogle Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342(8875), 821–828 (1993).
   Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. 333(25), 1670–1676 (1995).
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. 332(2), 80–85 (1995).
   PubMed Web of Science ®Google Scholar
• Nelson KM, Yeager BF. What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction? Ann. Pharmacother. 30(9), 986–993 (1996).
   Google Scholar
• Cody RJ. ACE inhibitors: myocardial infarction and congestive heart failure. Am. Fam. Physician 52(6), 1801–1806 (1995).
   Google Scholar
• Oldroyd KG, Pye MP, Ray SG et al. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am. J. Cardiol. 68(8), 713–718 (1991).
   Google Scholar
• Fukuzawa S, Ozawa S, Inagaki M, Sugioka J, Daimon M, Kushida S. Angiotensin-converting enzyme inhibitor therapy affects myocardial fatty acid metabolism after acute myocardial infarction. J. Nucl. Cardiol. 7(1), 23–28 (2000).
   Google Scholar
• Pinto YM, van Wijngaarden J, van Gilst WH, de Graeff PA, Wesseling H. The effects of short- and long- term treatment with an ACE-inhibitor in rats with myocardial infarction. Basic Res. Cardiol. 86(Suppl. 1), 165–172 (1991).
   PubMedGoogle Scholar
• Hu K, Gaudron P, Anders HJ et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc. Res. 39(2), 401–412 (1998).
   PubMed Web of Science ®Google Scholar
• Hoshida S, Yamashita N, Kuzuya T, Hori M. Differential effects of long-term renin–angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits. Atherosclerosis 149(2), 287–294 (2000).
   Google Scholar
• Coirault C, Langeron O, Lambert F et al. Impaired skeletal muscle performance in the early stage of cardiac pressure overload in rabbits: beneficial effects of angiotensin-converting enzyme inhibition. J. Pharmacol. Exp. Ther. 291(1), 70–75 (1999).
   Google Scholar
• Dominiak P, Blochl A. Does converting enzyme inhibition change the neuronal and extraneuronal uptake of catecholamines? Basic Res. Cardiol. 86(Suppl. 3), 149–156 (1991).
   Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high–risk patients. The Heart Outcomes Prevention Evaluation study Investigators. N. Engl. J. Med. 342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Spinale FG, de Gasparo M, Whitebread S et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. Circulation 96(7), 2385–2396 (1997).
   Google Scholar
• Shao Q, Panagia V, Beamish RE, Dhalla NS. Role of renin–angiotensin system in cardiac hypertrophy and failure. In: Angiotensin II Receptor Blockade: Physiological and Clinical Implications. Dhalla NS, Zahradka P, Dixon IM, Beamish RE (Eds). Kluwer Academic Publishers, MA, USA 283–310 (1998).
   Google Scholar
• Westlin W, Mullane K. Does captopril attenuates reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 77(6 Pt 2), I30–I39 (1988).
   Google Scholar
• Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18(6), 655–673 (2000).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 154–160 (2000).
   PubMed Web of Science ®Google Scholar
• Yamaguchi F, Sanbe A, Takeo S. Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction. Br. J. Pharmacol. 123(2), 326–334 (1998).
   PubMed Web of Science ®Google Scholar
• Mulder P, Devaux B, Richard V et al. Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling. Circulation 95(5), 1314–1319 (1997).
   Google Scholar
• Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation72(2), 406–412 (1985).
   PubMed Web of Science ®Google Scholar
• Coirault C, Langeron O, Lambert F et al. Impaired skeletal muscle performance in the early stage of cardiac pressure overload in rabbits: beneficial effects of angiotensin-converting enzyme inhibition. J. Pharmacol. Exp. Ther. 291(1), 70–75 (1999).
   Google Scholar
• Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan. Mol. Cell. Biochem. 254(1–2), 163–172 (2003).
   Google Scholar
• Shao Q, Ren B, Zarain-Herzberg A, Ganguly PK, Dhalla NS. Captopril treatment improves the sarcoplasmic reticular Ca2+ transport in heart failure due to myocardial infarction. J. Mol. Cell. Cardiol. 31(9), 1663–1672 (1999).
   PubMed Web of Science ®Google Scholar
• Shah KR, Ganguly PK, Netticadan T, Arneja AS, Dhalla NS. Changes in skeletal muscle SR Ca2+ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade. Can. J. Physiol. Pharmacol. 82(7), 438–447 (2004).
   Google Scholar
• Cody RJ. Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction. Arch. Intern. Med. 154(18), 2029–2036 (1994).
   Google Scholar
• Shao Q, Takeda N, Temsah N, Dhalla KS, Dhalla NS. Prevention of hemodynamic changes due to myocardial infarction by early treatment with imidapril. Cardiovasc. Pathobiol. 1(3), 180–186 (1996).
   Google Scholar
• Ren B, Lukas A, Shao Q et al. Electrocardiographic changes and mortality due to myocardial infarction in rats with or without imidapril treatment. J. Cardiovasc. Pharmacol. Ther. 3(1), 11–22 (1998).
   Google Scholar
• Schoemaker RG, Debets JJ, Struyker-Boudier HA, Smits JF. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J. Mol. Cell. Cardiol. 23(2), 187–197 (1991).
   Google Scholar
• Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the COoperative New Scandinavian ENalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. 327(10), 678–684 (1992).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N. Engl. J. Med. 341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348(14), 1309–1321 (2003).
   PubMed Web of Science ®Google Scholar
• Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J. Am. Coll. Cardiol. 27(3), 714–719 (1996).
   PubMed Web of Science ®Google Scholar
• Sanbe A, Tanonaka K, Kobayasi R, Takeo S. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J. Mol. Cell. Cardiol. 27(10), 2209–2222 (1995).
   PubMed Web of Science ®Google Scholar
• Raya TE, Fonken SJ, Lee RW et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am. J. Hypertens. 4(4 Pt 2), 334S–340S (1991).
   Google Scholar
• Jain P, Korlipara G, Mallavarapu C, Sikand V, Lillis O, Cohn PF. Effects of captopril therapy after late reperfusion on left ventricular remodeling after experimental myocardial infarction. Am. Heart J. 127(4 Pt 1), 756–763 (1994).
   Google Scholar
• McDonald KM, Chu C et al. Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction. J. Mol. Cell. Cardiol. 29(12), 3203–3210 (1997).
   Google Scholar
• Hugel S, Horn M, de Groot M et al. Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 277(6 Pt 2), H2167–H2175 (1999).
   Google Scholar
• Alhaddad IA, Sahgal P, Mir R, Brown EJ Jr. Early angiotensin converting enzyme inhibitor therapy enhances the benefits of late coronary artery reperfusion on infarct expansion. Coron. Artery Dis. 11(2), 183–189 (2000).
   Google Scholar
• Waltman TJ, Harris TJ, Cesario D, Ziegler M, Maisel AS. Effects of enalapril on T and B cell function in rats after myocardial infarction. J. Card Fail. 1(4), 293–302 (1995).
   Google Scholar
• Youn TJ, Kim HS, Oh BH. Ventricular remodeling and transforming growth factor-β 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade. Basic Res. Cardiol. 94(4), 246–253 (1999).
   Google Scholar
• Milanez MC, Gomes MG, Vassallo DV, Mill JG. Effects of captopril on interstitial collagen in the myocardium after infarction in rats. J. Card. Fail. 3(3), 189–197 (1997).
   Google Scholar
• Wang J, Liu X, Ren B, Rupp H, Takeda N, Dhalla NS. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J. Mol. Cell. Cardiol. 34(7), 847–857 (2002).
   Google Scholar
• Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89(5), 2273–2282 (1994).
   PubMed Web of Science ®Google Scholar
• Ali SM, Brown EJ Jr, Nallapati SR, Alhaddad IA. Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits. Coron. Artery Dis. 9(12), 815–821 (1998).
   Google Scholar
• Schieffer B, Wollert KC, Berchtold M et al. Development and prevention of skeletal muscle structural alterations after experimental myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 269(5 Pt 2), H1507–H1513 (1995).
   Google Scholar
• Wagner KD, Theres H, Born A et al. Contractile function of papillary muscle from rats with different infarct size after β-adrenergic blockade and ACE inhibition. J. Mol. Cell. Cardiol. 29(11), 2941–2951 (1997).
   Google Scholar
• Tappia PS, Liu SY, Shatadal S, Takeda N, Dhalla NS, Panagia V. Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Am J. Physiol. Heart Circ. Physiol. 277(1 Pt 2), H40–H49 (1999).
   Google Scholar
• Wang J, Liu X, Sentex E, Takeda N, Dhalla NS. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 284(6), H2277–H2287 (2003).
   Google Scholar
• Pitt B. Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure: implications for clinical practice. Cardiology 86(Suppl. 1), 41–45 (1995).
   Google Scholar
• Chiu AT, McCall DE, Price WA et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther.252(2), 711–718 (1990).
   PubMed Web of Science ®Google Scholar
• Siragy H. Angiotensin II receptor blockers: review of the binding characteristics. Am. J. Cardiol. 84(10A), S3–S8 (1999).
   Google Scholar
• Sweet CS, Rucinska EJ. Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur. Heart J. 15(Suppl. D), 139–144 (1994).
   Google Scholar
• Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am. J. Cardiol. 83(4), 477–481 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349(9054), 747–752 (1997).
   Google Scholar
• Dickstein K, Chang P, Willenheimer R et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J. Am. Coll. Cardiol.26(2), 438–445 (1995).
   PubMed Web of Science ®Google Scholar
• Warner JG Jr, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J. Am. Coll. Cardiol. 33(6), 1567–1572 (1999).
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor-α, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J. Am. Coll. Cardiol. 35(3), 714–721 (2000).
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Willenbrock R, Miric M et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am. Heart J. 145(3), E14 (2003).
   Google Scholar
• Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ. ADEPT: Addition of the AT1 receptor antagonist Eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am. Heart J. 141(5), 800–807 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor K, Patten RD, Smith JJ et al. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J. Cardiovasc. Pharmacol. 31(5), 654–660 (1998).
   Google Scholar
• Smits JF, van Krimpen C, Schoemaker RG et al. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J. Cardiovasc. Pharmacol.20(5), 772–778 (1992).
   PubMed Web of Science ®Google Scholar
• Jain M, Liao R, Ngoy S, Whittaker P, Apstein CS, Eberli FR. Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats. Cardiovasc. Res. 46(1), 66–72 (2000).
   PubMed Web of Science ®Google Scholar
• Hao J, Wang B, Jones SC, Jassal DS, Dixon IM. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am. J. Physiol Heart Circ. Physiol. 279(6), H3020–H3030 (2000).
   Google Scholar
• Thai HM, Van HT, Gaballa MA, Goldman S, Raya TE. Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Am. J. Physiol. Heart Circ. Physiol. 276(3 Pt 2), H873–H880 (1999).
   Google Scholar
• Ambrose J, Pribnow DG, Giraud GD, Perkins KD, Muldoon L, Greenberg BH. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. J. Cardiovasc. Pharmacol. 33(3), 433–439 (1999).
   Google Scholar
• Hamroff G, Katz SD, Mancini D et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 99(8), 990–992 (1999).
   PubMed Web of Science ®Google Scholar
• Shao Q, Saward L, Zahradka P, Dhalla NS. Ca2+ mobilization in adult rat cardiomyocytes by angiotensin type 1 and 2 receptors. Biochem. Pharmacol. 55(9), 1413–1418 (1998).
   Google Scholar
• Sudhir K, MacGregor JS, Gupta M et al. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies. Circulation 87(3), 931–938 (1993).
   Google Scholar
• Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 122(1), 59–67 (1996).
   PubMed Web of Science ®Google Scholar
• Stoll M, Steckelings UM, Paul M et al. The angiotensin AT2receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 95(2), 651–657 (1995).
   PubMed Web of Science ®Google Scholar
• Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J. Clin. Invest. 97(8), 1978–1982 (1996).
   Google Scholar
• Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360(9335), 752–760 (2002).
   Google Scholar
• Pfeffer MA, Swedberg K, Granger CB et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362(9386), 759–766 (2003).
   Google Scholar
• Tan LB, Schlosshan D, Williams SG. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT. Int. J. Clin. Pract. 58(2), 184–191 (2004).
   Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349(20), 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Unger T. Neurohormonal modulation in cardiovascular disease. Am. Heart J. 139(1 Pt 2), S2–S8 (2000).
   Google Scholar
• Kim S, Yoshiyama M, Izumi Y et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 103(1), 148–154 (2001).
   PubMed Web of Science ®Google Scholar
• Spinale FG, Mukherjee R, Iannini JP et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes. Circulation 96(7), 2397–2406 (1997).
   Google Scholar
• Dixon IM, Lee SL, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ. Res. 66(3), 782–788 (1990).
   PubMed Web of Science ®Google Scholar
• Dixon IM, Hata T, Dhalla NS. Sarcolemmal Na+K+-ATPase activity in congestive heart failure due to myocardial infarction. Am. J. Physiol Cell. Physiol. 262(3 Pt 1), C664–C671 (1992).
   Google Scholar
• Dixon IM, Hata T, Dhalla NS. Sarcolemmal calcium transport in congestive heart failure due to myocardial infarction in rats. Am. J. Physiol. Heart Circ. Physiol. 262(5 Pt 2), H1387–H1394 (1992).
   Google Scholar
• Afzal N, Dhalla NS. Differential changes in left and right ventricular SR calcium transport in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. 262(3 Pt 2), H868–H874 (1992).
   Google Scholar
• Geenen DL, Malhotra A, Scheuer J. Regional variation in rat cardiac myosin isoenzymes and ATPase activity after infarction. Am. J. Physiol. Heart Circ. Physiol. 256(3 Pt 2), H745–H750 (1989).
   Google Scholar
• El-Sabban ME, Hassan KA et al. Angiotensin II binding and extracellular matrix remodelling in a rat model of myocardial infarction. J. Renin Angiotensin Aldosterone Syst. 1(4), 369–378 (2000).
   Google Scholar
• Dhalla NS, Shao Q, Panagia V. Remodeling of cardiac membranes during the development of congestive heart failure. Heart Failure Rev.2(3), 261–272 (1998).
   Google Scholar
• Dixon IM, Ju H, Jassal DS, Peterson DJ. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol. Cell. Biochem. 165(1), 31–45 (1996).
   PubMed Web of Science ®Google Scholar
• Sharma SK, Chapman D, Temsah R, Netticadan T, Brasil DP, Dhalla NS. Prevention of vascular apoptosis in myocardial infarction by losartan. J. Cardiovasc. Pharmacol. Ther. 4(2), 77–84 (1999).
   Google Scholar
• Sethi R, Dhalla KS, Beamish RE, Dhalla NS. Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. 272(2 Pt 2), H884–H93 (1997).
   Google Scholar
• Sethi R, Elimban V, Chapman D, Dixon IM, Dhalla NS. Differential alterations in left and right ventricular G-proteins in congestive heart failure due to myocardial infarction. J. Mol. Cell. Cardiol. 30(11), 2153–2163 (1998).
   Google Scholar
• Sethi R, Shao Q, Takeda N, Dhalla NS. Attenuation of changes in G(i)-proteins and adenylyl cyclase in heart failure by an ACE inhibitor, imidapril. J. Cell. Mol. Med. 7(3), 277–286 (2003).
   Google Scholar
• Sethi R, Shao Q, Ren B Saini HK, Takeda N, Dhalla NS. Changes in β-adrenocetors in heart failure due to myocardial infarction are attenuated by blockade of renin–angiotensin system. Mol. Cell. Biochem. 263(1), 11–20 (2004).
   PubMed Web of Science ®Google Scholar
• Saini HK, Shao Q, Musat S, Takeda N, Tappia PS, Dhalla NS. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br. J. Pharmacol.144(2), 202–211 (2005).
   Google Scholar
• Sakai T, Li RK, Weisel RD et al. Autologous heart cell transplantation improves cardiac function after myocardial injury. Ann. Thorac. Surg. 68(6), 2074–2080 (1999).
   PubMed Web of Science ®Google Scholar
• Li RK, Jia ZQ, Weisel RD, Merante F, Mickle DA. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J. Mol. Cell. Cardiol. 31(3), 513–522 (1999).
   PubMed Web of Science ®Google Scholar
• Li RK, Mickle DA, Weisel RD et al. Natural history of fetal rat cardiomyocytes transplanted into adult rat myocardial scar tissue. Circulation 96(Suppl. II), II179–II187 (1997).
   Google Scholar